SITC Archive Library

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma 

01-04-2017 09:14

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.

Authors: Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood and Michael B. Atkins

Published as a position article and guidelines in the Journal for ImmunoTherapy of Cancer 2016 4:81.


Disclaimer:
Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.

#JournalforImmunoTherapyofCancer#RegisteredNurse#2016#Cytokines#Pharmacist
#PrimaryCarePhysician#AlliedHealth#Clinician#Pharmacist#ClinicalPracticeGuideline
#JournalArticle#RenalCellCarcinoma#SITCPublication

Statistics
0 Favorited
63 Views
0 Files
0 Shares
0 Downloads